Hem Securities Research has issued a decisive "SUBSCRIBE" recommendation for Sudeep Pharma Limited's initial public offering, valuing the company at a price band of Rs 563-593 per share—representin
ICICI Securities has reaffirmed its BUY rating on Lupin Ltd, setting a target price of Rs 2,275, reflecting a 15% upside from the current market price of Rs 1,975.
Motilal Oswal Financial Services has reiterated its BUY recommendation for Sun Pharma, assigning a 12-month target price of Rs 1,960, with the stock currently trading at Rs 1,690.
India’s biotechnology industry, one of the fastest-expanding sectors globally, is blazing new trails across healthcare, pharmaceuticals, and sustainability.
Motilal Oswal Financial Services has reiterated its BUY call on Laurus Labs, highlighting a robust earnings trajectory and strategic capital deployment in CDMO and generics segments.
